Are you offering durvalumab to patients with Stage III NSCLC with known targeted mutations (ie ALK, EGFR, ROS1, BRAF) after completion of chemoradiation per PACIFIC?   


Answer from: Medical Oncologist at Community Practice
Comments
Medical Oncologist at Virginia Cancer Specialists
With even lower numbers of patients with ALK gene ...
Sign in or Register to read more